[HTML][HTML] Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South …
…, G Kwatra, R Lazarus, AM Lawrie, A Lelliott, V Libri… - The Lancet, 2021 - thelancet.com
Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
[HTML][HTML] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a …
…, S Kerridge, A Koen, G Kwatra, R Lazarus, V Libri… - The Lancet, 2021 - thelancet.com
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
[HTML][HTML] Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV …
…, A Hicks, AA van der Klaauw, J Kwok, T Lambe, V Libri… - The Lancet, 2021 - thelancet.com
Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …
[HTML][HTML] Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised …
Background A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …
Neutralising antibody activity against SARS-CoV-2 VOCs B. 1.617. 2 and B. 1.351 by BNT162b2 vaccination
…, A Riddell, S Gamblin, M Howell, G Kassiotis, V Libri… - The Lancet, 2021 - thelancet.com
that emerged in the UK with the second COVID-19 wave in late 2020. The efficacy of currently
licensed COVID-19 vaccines against B. 1.617. 2 is unknown; although it possesses 12 …
licensed COVID-19 vaccines against B. 1.617. 2 is unknown; although it possesses 12 …
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a …
Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation. However, we have previously reported that heterologous …
mass COVID-19 immunisation. However, we have previously reported that heterologous …
[HTML][HTML] Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in …
…, H Hill, BM Horsington, T Lambe, R Lazarus, V Libri… - The Lancet, 2022 - thelancet.com
Background Given the importance of flexible use of different COVID-19 vaccines within the
same schedule to facilitate rapid deployment, we studied mixed priming schedules …
same schedule to facilitate rapid deployment, we studied mixed priming schedules …
[HTML][HTML] Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials …
Background COVID-19 vaccine supply shortages are causing concerns about compromised
immunity in some countries as the interval between the first and second dose becomes …
immunity in some countries as the interval between the first and second dose becomes …
[HTML][HTML] Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 …
…, AA van der Klaauw, N Kanji, V Libri… - The Lancet Infectious …, 2022 - thelancet.com
Background Some high-income countries have deployed fourth doses of COVID-19 vaccines,
but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We …
but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We …
[HTML][HTML] Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the …
…, D Hutton, N Jacobsen, K Joyce, R Kaminski, V Libri… - The Lancet, 2021 - thelancet.com
Background Concomitant administration of COVID-19 and influenza vaccines could reduce
burden on health-care systems. We aimed to assess the safety of concomitant administration …
burden on health-care systems. We aimed to assess the safety of concomitant administration …
